The Fairview Verdict: Telehealth Chest-Pain Follow-Up Becomes a Nine-Figure Exposure
A Hennepin County jury on Sept. 29, 2026, returned an $84 million verdict against Fairview Health Services, one of the largest medical malpractice awards in Minnesota history. The case involved a 53-year-old patient who died from complications of an exercise-induced heart attack after two encounters with a physician assistant: an October 2022 in-person visit for chest pain and a January 2023 telehealth follow-up.
Neither side disputed the applicable standard of care at trial. The entire dispute turned on whether the PA's examination, both in person and over video, met that standard given the patient's presenting symptoms. Jurors found breach and causation on both encounters, with damages weighted heavily toward lost future earning capacity.
For plaintiff counsel building telehealth-era malpractice dockets, the result confirms something simpler than a new doctrine: ordinary negligence framework applies in full to virtual visits, and documentation gaps during a telehealth follow-up for a chest-pain patient carry the same evidentiary weight as a missed physical exam. Fairview retains remittitur and appeal options, but the exposure signal has already landed with insurers statewide.
Case managers tracking similar fact patterns should flag any file involving chest pain, shortness of breath, or cardiac risk factors addressed partly or wholly by video visit. The AMA, American Telemedicine Association, and Federation of State Medical Boards already hold telehealth to the identical standard as in-person care, removing any argument that virtual follow-up deserves a lower bar.
Counsel handling cardiac-symptom telehealth files should treat Fairview as the new reference verdict for breach-and-causation damages modeling.
Daubert Housecleaning in the Baby Food MDL Narrows Causation Theories
In re Baby Food Products Liability Litigation (MDL 3101, N.D. Cal.), Judge Jacqueline Scott Corley on Oct. 15, 2026, granted summary judgment eliminating autism and ADHD causation claims after excluding five of six plaintiff causation experts under Daubert. IQ-loss and learning-disability theories survive for continued proceedings.
The ruling matters beyond baby food. Defense counsel in consumer-product mass torts now have a documented playbook: file Daubert challenges aimed squarely at causation experts before summary judgment briefing closes, rather than waiting for trial. A five-of-six exclusion rate rarely leaves a causation theory standing afterward.
Plaintiff firms with pending heavy-metal or neurotoxin product-liability inventory should audit expert retention now. A causation expert whose methodology cannot survive a focused Daubert motion is a liability to the entire inventory, not just the lead case, once a court applies MDL-wide rulings to satellite dockets.
The surviving IQ-loss and learning-disability claims give plaintiff firms a narrower but still viable path forward. Expect defense counsel in other product MDLs to cite Corley's order as the template for a pre-summary-judgment expert purge strategy.
Firms with neurotoxin or heavy-metal product inventory should pressure-test every retained causation expert against the Corley exclusion standard before a defendant does it first.
Colorado's New Damages Cap Schedule Resets the Settlement Math
Colorado's HB 24-1472 schedule steps the non-economic malpractice cap from $530,000 in 2026 to $645,000 in 2027, $760,000 in 2028, and $875,000 in 2029, then shifts to inflation adjustment. The wrongful-death medical-malpractice cap sits at $810,000 for 2026.
The total-damages cap is the greater of $1 million or 125 percent of the current non-economic figure, a formula that pushes upward every year the schedule runs. Colorado is no longer a nominal-cap jurisdiction; insurers and reinsurers writing Colorado med-mal lines need to rebuild reserve assumptions around a cap that now moves annually.
Plaintiff firms with Colorado med-mal inventory should recalculate settlement floors case by case rather than relying on 2024-era cap figures. A wrongful-death case valued under the old fixed cap may now clear settlement authority thresholds that defense carriers set years ago and have not revisited.
Expect carrier counsel to push for early mediation on cases filed before the 2027 step, since resolving now locks in the lower 2026 figure. Plaintiff counsel have the opposite incentive: delay where viable, provided statute-of-limitations and client needs allow it.
Colorado med-mal settlement authority built on pre-2026 cap figures is stale and should be re-run against the HB 24-1472 schedule before any demand goes out.
FDA Recalls Pile Up: Catheters, Capsules, and Surgical Packs
FDA's Class 2 recall expansion for Medline Industries reprocessed electrophysiology and ultrasound catheters, widened in October 2026, covers residual biological and chemical particulates linked to cerebral embolism, pulmonary embolism, DVT, and systemic infection risk. Hospitals and ASCs that used affected devices face product-liability exposure layered onto any procedure-specific negligence claim.
Medtronic/Given Imaging's Bravo CF esophageal pH capsule carries 184 serious injury reports on file with FDA tied to failure of the capsule to detach from its delivery catheter or attach properly to esophageal mucosa. GI and endoscopy practices should audit consent language and post-procedure monitoring now rather than after a claim arrives.
Alcon's Custom Pak ophthalmic procedure packs, recalled Class 2 in October over sterility and contamination concerns, affect outpatient cataract and vitreoretinal surgery centers. Facilities running affected lots should pull inventory, notify patients, and build a documented remediation file immediately; that paper trail separates a managed recall from a premises-liability complaint.
For plaintiff firms, each recall opens two intake tracks: direct device-injury claims against manufacturers and facility-negligence claims where a provider used a known-defective device after the recall notice issued. The second track carries a harder causation burden but a cleaner liability theory once notice timing is established.
Every open Medline, Medtronic, or Alcon recall should trigger an immediate records pull on any client who underwent a matching procedure in the affected window.
Telehealth Standard-of-Care Claims: The Cross-State Licensing Gap
Telehealth malpractice claims are running seven to ten times pre-pandemic volume in 2026, with misdiagnosis, failure-to-examine, and inadequate follow-up as the dominant theories, the same fact pattern underlying the Fairview verdict. AMA, ATA, and FSMB guidance holds telehealth to the identical standard of care as an in-person visit, closing off any argument that video medicine gets a lower bar.
An emerging procedural wrinkle complicates venue strategy: a provider licensed in one state treating a patient physically located in another can be sued in the patient's home state, where plaintiff counsel may find no local standard-of-care expert pool in that specialty. That gap cuts both ways, and defense counsel are beginning to exploit it on expert-qualification motions.
Firms building telehealth intake should map provider licensure against patient location at the time of the visit before filing, not after. Venue selection now carries an expert-availability dimension that simply did not exist when nearly all malpractice claims arose from single-state, in-person encounters.
Venue decisions on telehealth malpractice filings now hinge on expert-pool availability in the patient's state, a factor that did not matter three years ago.
Operations Note for Providers: LA County Lien Terms and SB 623
Providers treating rideshare-accident patients on lien or letter of protection in Los Angeles County have a hard 75-day window under SB 623's new Civil Code section 3333.9 before recovery is capped at the 70th-percentile FAIR Health benchmark for the relevant specialty and ZIP code. Providers who have already sold or transferred lien receivables face an additional cap tied to the consideration paid for that transfer.
Imaging centers, surgical groups, and pain-management practices carrying lien receivables on current LA County caseloads should run the FAIR Health benchmark analysis by specialty and ZIP before the window closes, not after a dispute arises. Itemized billing that does not meet the statute's documentation requirements is now a direct collection risk, independent of the underlying PI case outcome.
For firms placing clients with lien-based providers, the audit runs both directions: a provider who has not completed the benchmark review is a referral risk, and a lien-transfer agreement signed before the statute's effective date may already carry the lower consideration-based cap regardless of what the original lien stated. Both sides of the referral relationship need the same spreadsheet open at the same time.
This directory tracks which LA County imaging and surgical providers have published lien terms consistent with SB 623 compliance; firms vetting new lien relationships should confirm benchmark status before sending a client, not after the itemized bill arrives.
Every lien agreement signed in LA County before the SB 623 compliance deadline needs a second look, on both sides of the referral.